Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product

• Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2020-02, Vol.34 (1), p.65-75
• Main Authors: Kovács, Piroska, Schäfer, Tamás, Háda, Viktor, Hevér, Helga, Klingelhöfer, Sonja, Nebel, Merle, Stadie, Tanja, Kiss, Róbert, Urbányi, Zoltán
• Format: Article
• Language: English
• Subjects: Antibodies; Biological activity; Biological Factors - chemistry; Biological Factors - pharmacology; Biological products; Biomedical and Life Sciences; Biomedicine; Biosimilar Pharmaceuticals - chemistry; Biosimilar Pharmaceuticals - pharmacology; Bone growth; Cancer Research; Chromatography; Comparative analysis; European Union; FDA approval; Fractures; France; Humans; Marketing; Mass spectrometry; Molecular Medicine; Original; Original Research Article; Osteogenesis; Osteoporosis; Parathyroid; Parathyroid hormone; Peptides; Pharmaceuticals; Pharmacotherapy; Proteins; Quality; Scientific imaging; Teriparatide - chemistry; Teriparatide - pharmacology
• ISSN: 1173-8804; 1179-190X
• DOI: 10.1007/s40259-019-00386-x

Background In January 2017, the European Commission approved Terrosa ® (company code RGB-10) as one of the first biosimilar medicinal products of teriparatide for the same indications as for the reference medicinal product Forsteo ® (Lilly France S.A.S.), which has been on the market in the European Union since 2003. The active pharmaceutical ingredient of the reference medicinal product is the biologically active 1-34 fragment of the endogenous human parathyroid hormone [PTH(1-34)]. It is one of the three bone anabolic agents used in the treatment of osteoporosis promoting bone formation and preventing fragility fractures. Objective The objective of this paper is to summarise the results of the comparative analysis of representative batches of both the RGB-10 drug product and the reference medicinal product performed by physicochemical and in vitro biological methods. Methods A series of state-of-the-art analytical methods were applied in a comparative head-to-head manner for testing the similarity in respect to purity, content, structure and potency. Results Based on the results of the comprehensive physicochemical and biological characterisation, RGB-10 proved to be highly similar to the reference medicinal product with respect to the critical quality attributes investigated. Conclusion The results of the quality comparability study demonstrated similarity of RGB-10 to the reference medicinal product, providing the scientific basis for conducting a specifically designed clinical programme, and supported registration of the Marketing Authorisation Application of RGB-10 in the EU.